Resolvin D1 ameliorates hepatic steatosis by remodeling the gut microbiota and restoring the intestinal barrier integrity in DSS-induced chronic colitis

Zeng, Cui; Liu, Xinghuang; Zhu, Siran; Xiong, Danping; Zhu, Liangru; Hou, Xiaohua; Zou, Kaifang; Bai, Tao

doi:10.1016/j.intimp.2021.108500

Cited by 5 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RvD1, MaR1 as well as RvE1 are found to regulate lipid biosynthesis in hepatocytes ( Jung et al, 2014 ; Rius et al, 2017 ; Jung et al, 2018 ; Oh et al, 2022 ). In vivo , treatment with these SPMs led to reduced expression of FASn and ACC-1 and lower levels of liver TG ( Laiglesia et al, 2018 ; Rodriguez et al, 2020 ; Zeng et al, 2022 ). During liver injury, these SPMs display a hepatoprotective effect ( Figure 4 ) via attenuating the inflammatory responses, inhibiting hepatocyte apoptosis and oxidative stress ( Murakami et al, 2011 ; Zhang et al, 2015 ; Kuang et al, 2016 ; Wang et al, 2016 ; Li et al, 2020b ; Zhang et al, 2020b ; Soto et al, 2020 ; Tang et al, 2021 ; Hardesty et al, 2023 ).…”

Section: Biological Functions Of Oxylipins In Liver Disease and Cance...mentioning

confidence: 99%

Eicosanoids and other oxylipins in liver injury, inflammation and liver cancer development

et al. 2023

View full text Add to dashboard Cite

Liver cancer is a malignancy developed from underlying liver disease that encompasses liver injury and metabolic disorders. The progression from these underlying liver disease to cancer is accompanied by chronic inflammatory conditions in which liver macrophages play important roles in orchestrating the inflammatory response. During this process, bioactive lipids produced by hepatocytes and macrophages mediate the inflammatory responses by acting as pro-inflammatory factors, as well as, playing roles in the resolution of inflammation conditions. Here, we review the literature discussing the roles of bioactive lipids in acute and chronic hepatic inflammation and progression to cancer.

show abstract

Section: Biological Functions Of Oxylipins In Liver Disease and Cance...mentioning

confidence: 99%

Eicosanoids and other oxylipins in liver injury, inflammation and liver cancer development

et al. 2023

View full text Add to dashboard Cite

show abstract

“…BLT1 can serve as a receptor for RvE1, accelerating the intestinal epithelial barrier repair ( 199 ). RvD1, sourced from DHA, confers protection against IBD by strengthening tight junctions, maintaining intestinal homeostasis, and attenuating inflammation ( 120 ). RvD1 also reduces mesenchymal transition of intestinal epithelium and prevents IBD-associated fibrosis ( 121 ).…”

Section: Lipid Derive Mediatorsmentioning

confidence: 99%

Fatty acids and lipid mediators in inflammatory bowel disease: from mechanism to treatment

Yan,

Ye,

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Inflammatory Bowel Disease (IBD) is a chronic, relapsing inflammatory disorder of the gastrointestinal tract. Though the pathogenesis of IBD remains unclear, diet is increasingly recognized as a pivotal factor influencing its onset and progression. Fatty acids, essential components of dietary lipids, play diverse roles in IBD, ranging from anti-inflammatory and immune-regulatory functions to gut-microbiota modulation and barrier maintenance. Short-chain fatty acids (SCFAs), products of indigestible dietary fiber fermentation by gut microbiota, have strong anti-inflammatory properties and are seen as key protective factors against IBD. Among long-chain fatty acids, saturated fatty acids, trans fatty acids, and ω-6 polyunsaturated fatty acids exhibit pro-inflammatory effects, while oleic acid and ω-3 polyunsaturated fatty acids display anti-inflammatory actions. Lipid mediators derived from polyunsaturated fatty acids serve as bioactive molecules, influencing immune cell functions and offering both pro-inflammatory and anti-inflammatory benefits. Recent research has also highlighted the potential of medium- and very long-chain fatty acids in modulating inflammation, mucosal barriers, and gut microbiota in IBD. Given these insights, dietary intervention and supplementation with short-chain fatty acids are emerging as potential therapeutic strategies for IBD. This review elucidates the impact of various fatty acids and lipid mediators on IBD and delves into potential therapeutic avenues stemming from these compounds.

show abstract

Dihydroartemisinin Modulates Enteric Glial Cell Heterogeneity to Alleviate Colitis

Qiu,

Chang,

Chen

et al. 2024

Advanced Science

View full text Add to dashboard Cite

The precise mechanism underlying the therapeutic effects of dihydroartemisinin (DHA) in alleviating colitis remains incompletely understood. A strong correlation existed between the elevation of glial fibrillary acidic protein (GFAP)+/S100 calcium binding protein B (S100β)+ enteric glial cells (EGCs) in inflamed colonic tissues and the disruption of the intestinal epithelial barrier (IEB) and gut vascular barrier (GVB) observed in chronic colitis. DHA demonstrated efficacy in restoring the functionality of the dual gut barrier while concurrently attenuating intestinal inflammation. Mechanistically, DHA inhibited the transformation of GFAP+ EGCs into GFAP+/S100β+ EGCs while promoting the differentiation of GFAP+/S100β+ EGCs back into GFAP+ EGCs. Furthermore, DHA induced apoptosis in GFAP+/S100β+ EGCs by inducing cell cycle arrest at the G0/G1 phase. The initial mechanism is further validated that DHA regulates EGC heterogeneity by improving dysbiosis in colitis. These findings underscore the multifaceted therapeutic potential of DHA in ameliorating colitis by improving dysbiosis, modulating EGC heterogeneity, and preserving gut barrier integrity, thus offering promising avenues for novel therapeutic strategies for inflammatory bowel diseases.

show abstract

Resolvin D1 ameliorates hepatic steatosis by remodeling the gut microbiota and restoring the intestinal barrier integrity in DSS-induced chronic colitis

Cited by 5 publications

References 43 publications

Eicosanoids and other oxylipins in liver injury, inflammation and liver cancer development

Eicosanoids and other oxylipins in liver injury, inflammation and liver cancer development

Fatty acids and lipid mediators in inflammatory bowel disease: from mechanism to treatment

Dihydroartemisinin Modulates Enteric Glial Cell Heterogeneity to Alleviate Colitis

Contact Info

Product

Resources

About